Aromatase Inhibitor–Associated Arthralgia and/or Bone Pain: Frequency and Characterization in Non–Clinical Trial Patients

A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast Cancer

R. Charles Coombes, Emma Hall, Lorna J. Gibson et al. · New England Journal of Medicine · 2004 · 1.8K citations · Full text

Pharmacy, Endocrinology, Oncology +13

Neoadjuvant Treatment of Postmenopausal Breast Cancer With Anastrozole, Tamoxifen, or Both in Combination: The Immediate Preoperative Anastrozole, Tamoxifen, or Combined With Tamoxifen (IMPACT) Multicenter Double-Blind Randomized Trial

Ian E. Smith, Mitch Dowsett, S. Ebbs et al. · Journal of Clinical Oncology · 2005 · 772 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Double-Blind, Randomized Trial Comparing the Efficacy and Tolerability of Fulvestrant Versus Anastrozole in Postmenopausal Women With Advanced Breast Cancer Progressing on Prior Endocrine Therapy: Results of a North American Trial

C. Kent Osborne, John Pippen, Stephen E. Jones et al. · Journal of Clinical Oncology · 2002 · 643 citations

Medicine, Oncology, Pharmacology +14

Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate.

P Dombernowsky, I E Smith, Geoffrey Falkson et al. · Journal of Clinical Oncology · 1998 · 640 citations

Medicine, Oncology, Pharmacology +16

Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group.

A. U. Buzdar, W. Jonat, Anthony Howell et al. · Journal of Clinical Oncology · 1996 · 410 citations · Full text

Pharmacy, Oncology, Pharmacology +16